Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01463423 · ClinicalTrials.gov registry record · NA
Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 256
- Enrollment target
NCT01463423: Completed NA study, sponsored by Stanford University.
NCT01463423 is a NA study that has completed, run by Stanford University. The registered enrollment target is 256 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01463423, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 256 participants
- Enrollment target
Study Summary
A research study of a procedure to treating lung cancer with focused radiation called Stereotactic Ablative Radiotherapy (SABR). The purpose of this study is to evaluate the effectiveness of individualizing the dose of radiation used to treat lung tumors with SABR based on tumor-specific factors. While recent research has identified SABR as a promising method to increase local control (LC) of lung cancer, further research has indicated that tumor volume is a prognostic factor, with increased size/volume of tumor being associated with poorer outcomes. This study explores if a volume-adapted strategy for the radiologic exposure (dose) will improve efficacy in larger tumors (ie, \> 10 cc). This is a study of the procedure stereotactic ablative radiotherapy (SABR). It is not a study of a specific drug or device.
Interventions
- RADIATION iSABR, 25 Gray in 1 fraction for small peripheral tumors
- RADIATION iSABR, 50 Gray in 4 fractions for medium peripheral tumors
- RADIATION iSABR, 54 Gray in 3 fractions for large peripheral tumors
- RADIATION iSABR, 40 Gray in 4 fractions for small central tumors
- RADIATION iSABR, 50 Gray in 4 fractions for medium central tumors
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2011-10-21 |
| Est. Completion | 2022-02-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01463423
The ClinicalTrials.gov registry entry for NCT01463423 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 256 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which iSABR, 25 Gray in 1 fraction for small peripheral tumors is the first listed.
NCT01463423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01463423 about?
NCT01463423 is a clinical study titled "Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)". A research study of a procedure to treating lung cancer with focused radiation called Stereotactic Ablative Radiotherapy (SABR). The purpose of this study is to evaluate the effectiveness of individualizing the dose of radiation used to treat lung tumors with SABR based on tumor-specific factors. W...
What is the current status of trial NCT01463423?
This trial is currently completed. It is a NA study. The enrollment target is 256 participants. The study started on 2011-10-21. Estimated completion is 2022-02-07.
What interventions are being tested in trial NCT01463423?
The interventions under investigation include: iSABR, 25 Gray in 1 fraction for small peripheral tumors (RADIATION), iSABR, 50 Gray in 4 fractions for medium peripheral tumors (RADIATION), iSABR, 54 Gray in 3 fractions for large peripheral tumors (RADIATION), iSABR, 40 Gray in 4 fractions for small central tumors (RADIATION), iSABR, 50 Gray in 4 fractions for medium central tumors (RADIATION).
Who is sponsoring clinical trial NCT01463423?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.